Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Limited systemic sclerosis (lSSc) (or SSc sine scleroderma) is a subset of systemic sclerosis (SSc) characterized by organ involvement in the absence of fibrosis of the skin.
Biomarker and diagnostic research for limited systemic sclerosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily industry-sponsored.
164 publications have been identified in PubMed for limited systemic sclerosis. Research spans Review / Meta-Analysis (33%), Epidemiology / Natural History (19%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 45 | 33% |
Data assembled from 4 of 12 sources · Last updated Nov 3, 2026, 7:20 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression |
26 |
19% |
Patient case studies | 18 | 13% |
Laboratory research | 16 | 12% |
Testing and diagnosis research | 15 | 11% |
Clinical study results | 11 | 8% |
Other research | 4 | 3% |
New treatment approaches | 3 | 2% |
Melideo HM (2026). [PMID: 42037288](https://pubmed.ncbi.nlm.nih.gov/42037288/). *G Ital Nefrol*. [Case Report / Case Series]
Kjærsgaard Andersen R (2026). [PMID: 41405899](https://pubmed.ncbi.nlm.nih.gov/41405899/). *JAMA Dermatol*. [Diagnostic / Biomarker]
Morales-Pertuz C (2026). [PMID: 41772467](https://pubmed.ncbi.nlm.nih.gov/41772467/). *BMC Infect Dis*. [Case Report / Case Series]
Huang J (2026). [PMID: 41451447](https://pubmed.ncbi.nlm.nih.gov/41451447/). *Arthritis Rheumatol*. [Basic Science / Preclinical]
Wang J (2026). [PMID: 41483081](https://pubmed.ncbi.nlm.nih.gov/41483081/). *Clin Rheumatol*. [Other]
Kleefeld F (2026). [PMID: 41934478](https://pubmed.ncbi.nlm.nih.gov/41934478/). *Acta Neuropathol*. [Basic Science / Preclinical]
Nigro A (2026). [PMID: 41712154](https://pubmed.ncbi.nlm.nih.gov/41712154/). *Intern Emerg Med*. [Case Report / Case Series]
Foeldvari I (2026). [PMID: 41638996](https://pubmed.ncbi.nlm.nih.gov/41638996/). *Best Pract Res Clin Rheumatol*. [Review / Meta-Analysis]
Radić M (2026). [PMID: 41682782](https://pubmed.ncbi.nlm.nih.gov/41682782/). *J Clin Med*. [Review / Meta-Analysis]
Quigley EMM (2026). [PMID: 41997504](https://pubmed.ncbi.nlm.nih.gov/41997504/). *Gastroenterology*. [Review / Meta-Analysis]
AI-curated news mentioning limited systemic sclerosis
Updated Oct 23, 2026
Recent studies highlight emerging drugs in phase 2/3 and selected phase 1/2 trials for systemic sclerosis treatment. These developments may offer new therapeutic options for patients suffering from this challenging condition.
The World Scleroderma Congress highlighted emerging paradigms in the understanding and treatment of systemic sclerosis. New research findings may influence future therapeutic strategies for this complex autoimmune disease.
A recent study published in PubMed highlights health literacy levels among individuals with systemic sclerosis, utilizing data from the Scleroderma Patient-Centered Intervention Network (SPIN). This cross-sectional study aims to inform future interventions to improve patient outcomes.